Global Cystic Fibrosis Market Value To More Than Treble By 2019, Says GBI Research

Published: Mar 11, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK (GBI Research), 11 March 2014 -- The global Cystic Fibrosis (CF) market value in the seven major countries (7MM: the US, Canada, France, Germany, Italy, Spain and the UK) will jump from $1.2 billion in 2013 to just under $4.5 billion by 2019, at a massive Compound Annual Growth Rate (CAGR) of 30.4%, says a new report from business intelligence provider GBI Research.

According to the report*, the five European Union (5EU) countries will show the most growth in the CF market, with their total value climbing from $568 million in 2013 to just over $2.2 billion by 2019, at a CAGR of 32.3%. The UK and Spain will have the region’s highest CAGRs of 34.4% and 33.9%, respectively.

The 5EU countries will be followed by the US, with its CF market value expected to increase from $636 million in 2013 to $2.2 billion by 2019, at a CAGR of 28.6%.

Joshua Libberton, Analyst for GBI Research, says that this rapid market expansion is due to powerful drugs entering the CF treatment arena, particularly novel disease-modifying Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators.

“Although very expensive, CFTR modulators are the first agents to act directly on the defective CFTR protein, which is the root cause of CF. As a result, they represent the closest therapy to a cure that is currently available to CF patients,” Libberton says.

GBI Research states that one CFTR modulator, Kalydeco (ivacaftor), which was launched in 2012, has become one of the top-grossing drugs in the CF market, following a jump in value from $700 million in 2012 to $1.2 billion in 2013. The introduction of other CFTR modulators during the forecast period, such as lumacaftor and Ataluren, will further boost the market.

Libberton concludes: “CFTR modulators are set to have the largest impact on the industry, but other high-profile pipeline drugs, including antibiotics Aeroquin and Arikace, will also benefit the market. With the increasing life expectancy of CF patients, there is an ever-expanding treatment population for these therapies to target over the coming years.”

*Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth

This report provides analysis of the Cystic Fibrosis (CF) market and pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The CF clinical trial landscape is also analyzed, with a particular emphasis on failure rates across different trial phases as well as the trends in clinical trial size and duration. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.


GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. For more information, please contact our Press Office on +44 (0)1204 543 537 or at

Help employers find you! Check out all the jobs and post your resume.

Back to news